Asset profile
HY209gel
Small molecule
Evidence outlook · results not reported
NCT06024499 · Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT06024499: The study randomized 210 participants to two HY209gel doses or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in EASI score at Week 8, but the comparison and treatment effects have not yet been reported.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 35 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HY209gel: this drug | Phase 2 | Small molecule | GPCR19 / GPBAR1 (TGR5, bile acid receptor) | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | ||
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| ADSTEM | Phase 3 | Cell therapy | autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy | ||
| Afimkibart | Phase 3 | Monoclonal antibody | TL1A | ||
| Asivatrep | Phase 3 | Small molecule | TRPV1 |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.